Quote
519.51
+4.07 (+0.79%)
We have scored 73 news catalysts on VRTX (VRTX) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.44). Most of the impact sits in sector healthcare and price momentum.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
514.65–525.29
Open
522.17
Prev close
515.44
Volume
813.3K
Avg volume
—
Dividend
—
IPO
—
No scored news tagged VRTX or its network in the window yet.
Show more VRTX articles →Analysts publish price targets on VRTX, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
14 analyst price targets from $350 to $665
as of 2026-09-04
The market is within 2% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about VRTX — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of VRTX, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for VRTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits at the 29th percentile of the 14 published models, just 2% below the median, meaning it broadly agrees with the middle of the street but explicitly rejects the most bullish growth scenarios and the most bearish decline assumptions.
What the disagreement turns on
Whether the Crinetics assets and the broader pipeline can accelerate revenue growth fast enough to meet the 15.8% annual rate the price already requires, which cannot be settled by the wired data because unit volumes for unreleased drugs are not yet measurable.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $558 on 2026-09-04 — the quote has since moved -7%, so read this as a record of what was priced in then, not now.
